Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.

scientific article published on 13 March 2013

Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4088/JCP.12M08084
P8608Fatcat IDrelease_lzu6swqpajc3tanznjpqzi44uu
P698PubMed publication ID23541189

P50authorStephen StahlQ24006564
P2093author name stringAndrei Pikalov
Antony Loebel
Josephine Cucchiaro
Jay Hsu
Doreen Simonelli
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectschizophreniaQ41112
placeboQ269829
P304page(s)507-515
P577publication date2013-03-13
P1433published inThe Journal of Clinical PsychiatryQ7743563
P1476titleEffectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
P478volume74

Reverse relations

cites work (P2860)
Q36489406A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
Q36475355A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Q30353864A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
Q41546064Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Q38826206BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.
Q39009497Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
Q89145780Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Q35728228Clinical pharmacology of atypical antipsychotics: an update.
Q36990173Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Q34073723Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
Q47733836Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
Q34515834LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
Q89128745Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
Q99402127Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia
Q35544274Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
Q38537910Lurasidone in the treatment of schizophrenia: a critical evaluation
Q36444832Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
Q47623090Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders
Q92102152Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
Q39015229Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis
Q38224339Safety of antipsychotic drugs: focus on therapeutic and adverse effects
Q26738850Schizophrenia relapse, patient considerations, and potential role of lurasidone
Q94547427Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
Q34477219The clinical utility of lurasidone in schizophrenia: patient considerations
Q33619940The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
Q34486175Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
Q42682470Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

Search more.